800-331-6634

Our Clinical Trials

Below is a listing of our studies that are currently enrolling new patients.

Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov

 

Wet AMD (Age Related Macular Degeneration)

  • RGX-314 Sponsored by RegenxBio
    The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.
  • DAWN
    A previous pilot study demonstrated that commonly available glaucoma drops (dorzolamide-timolol) might decrease the amount of chronic swelling in patient with wet age-related macular degeneration who have been receiving anti-vascular endothelial growth factor (VEGF) injections. This will be a larger study where subjects are randomly assigned to receive the glaucoma drops or a placebo (artificial tears) in order to confirm whether this previous finding is valid.
  • Opthea
    A multicenter, randomized, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
  • Ophthotech 2007
    To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (nAMD)

 

Dry AMD (Age Related Macular Degeneration)

  • Ophthotech 2003 Sponsored by Ophthotech
    The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD)
  • TOGA Sponsored by the University of Virginia
    Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

 

Uveitis

  • MERIT Sponsored by The Must Research Group
    Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)
  • Gilead
    The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis.

 

Retinal Vein Occlusion

  • SAPPHIRE Sponsored by Clearside
    Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO .

 

Stargardt's Macular Degeneration

  • Opthotech 2005
    To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

 

Diabetic Macular Edema

  • AC Switch
    A DRCR Study - To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

 

Diabetic Retinopathy

  • Eyenuk
    EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.

 

Retinal Detachment/Macular Hole/Epiretinal Membrane

  • Inflammasomes
    Prospective study evaluating the role of inflammasomes in cell death in retinal detachment, full thickness macular hole, and epiretinal membrane.


Retinitis Pigmentosa

  • Argus
    This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to include all eligible and willing subjects implanted with Argus II System in the United States.